Ayvakit is owned by Blueprint Medicines.
Ayvakit contains Avapritinib.
Ayvakit has a total of 3 drug patents out of which 0 drug patents have expired.
Ayvakit was authorised for market use on 09 January, 2020.
Ayvakit is available in tablet;oral dosage forms.
Ayvakit can be used as treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leukemia (mcl).
Drug patent challenges can be filed against Ayvakit from January, 2024.
The generics of Ayvakit are possible to be released after 15 October, 2034.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9944651 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) | |
US9994575 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) | |
US9200002 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 9, 2025 |
New Indication (I) | Jun 16, 2024 |
Orphan Drug Exclusivity (ODE) | Jan 9, 2027 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: January, 2024
Market Authorisation Date: 09 January, 2020
Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leukemia (mcl)
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic